A randomised, controlled trial of bosentan in severe COPD.
about
Endothelin receptor antagonists for pulmonary arterial hypertensionPulmonary Hypertension Due to Common Respiratory Conditions: Classification, Evaluation and Management StrategiesPulmonary vasculature in COPD: The silent componentPulmonary hypertension survival effects and treatment options in cystic fibrosisAn official American Thoracic Society/American College of Chest Physicians policy statement: the Choosing Wisely top five list in adult pulmonary medicineRight ventricular dysfunction in chronic lung diseaseCardiopulmonary coupling in chronic obstructive pulmonary disease: the role of imaging.Pulmonary hypertension and right heart dysfunction in chronic lung disease.Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension.Impact of pulmonary artery pressure on exercise function in severe COPD.The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease.Adenosine A2B receptor and hyaluronan modulate pulmonary hypertension associated with chronic obstructive pulmonary diseasePulmonary arterial remodeling in chronic obstructive pulmonary disease is lobe dependent.Combined pulmonary fibrosis and emphysema.Pulmonary heart disease: The heart-lung interaction and its impact on patient phenotypes.Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomicsManagement of acute right ventricular failure in the intensive care unitBosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumoniaAcute effects of aerosolized iloprost in COPD related pulmonary hypertension - a randomized controlled crossover trialEffects of different pulmonary vasodilators on arterial saturation in a model of pulmonary hypertension.Vasodilatory effect of the stable vasoactive intestinal peptide analog RO 25-1553 in murine and rat lungsGeometry of the randomized evidence for treatments of pulmonary hypertension.Therapy in stable chronic obstructive pulmonary disease patients with pulmonary hypertension: a systematic review and meta-analysis.Lung transplantation for pulmonary hypertension.Na(+)/H(+) exchange and hypoxic pulmonary hypertension.17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects.Severe Pulmonary Arteriopathy Is Associated with Persistent Hypoxemia after Pulmonary Endarterectomy in Chronic Thromboembolic Pulmonary Hypertension.Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta-Analysis of 4894 Patients From 24 Randomized Double-Blind Placebo-Controlled Clinical Trials.Pulmonary Hypertension Secondary to COPD.The role of pulmonary arterial stiffness in COPD.Pulmonary hypertension in parenchymal lung disease.Pharmacotherapies for COPD.Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial.Systematic review and meta-analysis of pulmonary hypertension specific therapy for exercise capacity in chronic obstructive pulmonary diseasePathophysiology and clinical implications of pulmonary arterial enlargement in COPDMeta-analysis of randomized controlled trials of bosentan for treatment of pulmonary arterial hypertension.Update on pulmonary hypertension complicating chronic obstructive pulmonary diseaseSafety and tolerability of bosentan in the management of pulmonary arterial hypertension.Update in chronic obstructive pulmonary disease 2008.Pulmonary hypertension in COPD: a review and consideration of the role of arterial vasodilators.
P2860
Q24200714-A5776EF3-8A4E-49C9-B765-122958D369DBQ26738405-6CB44571-094E-47BE-8F16-93D9870C53A0Q26749309-F7FB1FD2-0F12-4813-A903-C7CC15CE27A8Q26825432-ADF04155-39CB-42CD-8355-869E4419017DQ26829758-057FBF3F-5EC7-49C1-ACC0-7DC630BBE239Q27002670-1A811428-CA33-435F-A792-98E3AAB83BB0Q30417798-A5F8C39A-3ABC-46E1-9AEB-71B6C72CB9F6Q30432299-26C2BB3C-B280-496A-8233-F6C51FC456CFQ33594460-8AC3AC40-76A9-4011-B231-70EA32BAEAC7Q33637604-7792DF3F-90F5-49BB-81F9-284205FEC12DQ33738555-F779D410-880F-48DF-B317-1F9C22209B4CQ33765096-3C5269C6-9FC4-4B1A-AE66-02581D74107EQ33806097-4C04375A-9BA1-40A1-BDD4-91E80025D2A6Q34325239-73B72ECC-EA4F-48B9-AE63-0409B815590DQ34343972-733E7B15-4BB2-4776-912C-6C6CD0805ED2Q34344390-62060EBC-DB1B-4BC2-AF6A-E46A38CDAD79Q34479233-ECF77D6B-5026-4547-A063-CFA8ABE5D5ECQ34480466-1B126260-9BB1-4E1A-8AAD-EAFD6E4DC3DDQ34540493-929D9060-6EA9-4569-AFD8-0838C0AC5CD8Q34981737-98A38C75-B453-4DB6-AD56-3B75B909FE74Q34999736-3DF506C4-9979-4193-BC2D-4F8C1C96745FQ35013676-1050B3D7-8ADA-4009-8B63-A9DCB7AA4278Q35290234-59C0D147-0BEB-4E37-A6BD-A329827FC0E7Q35412426-98AD21CB-1A6F-479A-8FFB-191E6B40657DQ35665720-3557B535-1906-45A3-B778-2E1BA66BAC71Q35987282-8836A9AA-020B-41AE-AB4B-158AD8B8B4DBQ36115857-2185EEE0-1B84-4ED1-A078-4FFC26C23175Q36212186-37DDCD5B-7D02-42CE-851D-5B28DCFF1755Q36221051-447D6AF9-B05A-4415-890E-A2CDA56AF40EQ36284886-31C5A252-3890-4195-A664-D9EF200AEA2EQ36328903-8A5E6B72-22B9-43B4-9B8D-483FE7CEEE9BQ36843717-B61A35C3-9615-4FFB-867A-743F47ADEFE8Q36997160-36912942-80CC-428A-AFB9-9E0831AE080BQ37098096-451C322B-7EF1-4FF4-BC73-00D742A8AEE2Q37304910-399CFBEC-A5CF-41F4-B53A-5508CE688C8AQ37356518-62712D8A-F443-4356-9431-A1A0716BD26EQ37367652-F8B98173-07D4-4F75-8F8B-FF1EFFE4DC88Q37403190-7C5DF6B1-9D5D-4EB9-98CD-8AB9FE890672Q37422824-23F65886-2973-4AEB-8114-E63A85CCC55EQ37451068-005BBB1D-9DE4-4087-BF28-04A63CC1E614
P2860
A randomised, controlled trial of bosentan in severe COPD.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
A randomised, controlled trial of bosentan in severe COPD.
@en
A randomised, controlled trial of bosentan in severe COPD.
@nl
type
label
A randomised, controlled trial of bosentan in severe COPD.
@en
A randomised, controlled trial of bosentan in severe COPD.
@nl
prefLabel
A randomised, controlled trial of bosentan in severe COPD.
@en
A randomised, controlled trial of bosentan in severe COPD.
@nl
P2093
P1476
A randomised, controlled trial of bosentan in severe COPD
@en
P2093
P304
P356
10.1183/09031936.00011308
P577
2008-04-30T00:00:00Z